ArticleAntimicrobial agents and chemotherapy2015
Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion protein.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Is the Association of Granzyme B and the Exported Parasite Hsp70 a Possible Trojan Horse of Severe Malaria?Advances in experimental medicine and biology · 2026Article
- Human granzyme B binds Plasmodium falciparum Hsp70-x and mediates antiplasmodial activity in vitro.Cell stress & chaperones · 2023Article
- Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.Science translational medicine · 2023Article
- Engineered antibody fusion proteins for targeted disease therapy.Trends in pharmacological sciences · 2021Review
- Generation of a novel affibody molecule targeting Chlamydia trachomatis MOMP.Applied microbiology and biotechnology · 2021Article
- γδ T Cells KillJournal of immunology (Baltimore, Md. : 1950) · 2020Article
- Memory CD73+IgM+ B cells protect against Plasmodium yoelii infection and express Granzyme B.PloS one · 2020Article
- Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.Journal of experimental & clinical cancer research : CR · 2019Article
- A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.Theranostics · 2019Article
- Heat Shock Proteins as Immunomodulants.Molecules (Basel, Switzerland) · 2018Review
- Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases.Frontiers in microbiology · 2018Review
- Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics.Antibiotics (Basel, Switzerland) · 2017Review
- Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.Biomedicines · 2017Review
- Article
- Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1.Scientific reports · 2016Article
- Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10.Malaria journal · 2015Article
- A High Yield and Cost-efficient Expression System of Human Granzymes in Mammalian Cells.Journal of visualized experiments : JoVE · 2015Article
- Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody.Malaria journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present here the first evidence that granzyme B acts against Plasmodium falciparum (50% inhibitory concentration [IC50], 1,590 nM; 95% confidence interval [95% CI], 1,197 to 2,112 nM). We created a novel antimalarial fusion protein consisting of granzyme B fused to a merozoite surface protein 4 (MSP4)-specific single-chain Fv protein (scFv), which targets the enzyme to infected erythrocytes, with up to an 8-fold reduction in the IC50 (176 nM; 95% CI, 154 to 202 nM). This study confirms the therapeutic efficacies of recombinant antibody-mediated antimalarial immunotherapeutics based on granzyme B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.